GLUCOCORTICOIDS AND MINERALOCORTICOIDS IN BLOOD PLASMA AS MARKERS FOR THE EARLY DIAGNOSIS OF ADRENAL CORTEX TUMORS
DOI:
https://doi.org/10.15407/oncology.2023.04.277Keywords:
adrenocortical adenoma, adrenal glands, cortisol, aldosterone, adrenocorticotropic hormone, reninAbstract
Summary: Aim: assessment of the pituitary-adrenal and renin-aldosterone systems state in patients with various types of adrenocortical adenomas. Object and methods: in 35 patients with adrenocortical adenomas, the hormonal status was evaluated by a direct quantitative immunoenzymatic analysis. The levels of glucocorticoids (cortisol) and mineralocorticoids (aldosterone) were determined. The levels of adrenocorticotropic hormone (ACTH) and renin were assessed by immunochemical methods using monoclonal antibodies specific for ACTH and renin. Results: increasing level of the cortisol against the background of a decreasing level of the ACTH in patients with cortisol-producing adrenocortical adenomas was revealed. In patients with aldosterone-producing adenomas, aldosteronism develops against the background of an unchanged level of renin and an increase in the aldosterone-renin ratio. Conclusions: the occurrence of hormone-dependent adenomas in the adrenal cortex disrupts the functioning of the pituitary-adrenal and renin-aldosterone systems, which serves as a criterion for the early diagnosis of adrenocortical adrenal adenomas.
References
Sherlock M, Scarsbrook A, Abbas A, al. Adrenal incidentaloma. Endocr Rev 2020; 41 (6): 775–820. https://doi.org/10.1210/endrev/bnaa008
Almeida M, Bezerra-Neto J, Mendonça B, al. Primary malignant tumors of the adrenal glands. Clinics (Sao Paulo) 2018; 73 (suppl 1): e756s. https://doi.org/10.6061/clinics/2018/e756s
Dong R, Yang R, Zhan Y, et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell 2018; 38 (5): 716–33.e6. https://doi.org/10.1016/j.ccell.2020.08.014
Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal incidentaloma. Endocr Rev 2020; 41 (6): 775–820. https://doi.org/10.1210/endrev/bnaa008
Ross I, Louw G. Embryological and molecular development of the adrenal glands. Clin Anat 2015; 28 (2): 235–42. https://doi.org/10.1002/ca.22422
Hodgson A, Pakbaz S, Mete O. A diagnostic approach to adrenocortical tumors. Surg Pathol Clin 2019; 12 (4): 967–95. https://doi.org/10.1016/j.path.2019.08.005
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of adrenal tumors. Eur J Endocrinol 2016; 175 (2): G1–G34. https://doi.org/10.1530/EJE-16-0467
Ishiwata K, Suzuki S, Igarashi K, et al. Characteristics of benign adrenocortical adenomas with 18F-FDG PET accumulation. Eur J Endocrinol 2021; 185 (1): 155–65. https://doi.org/10.1530/EJE-20-1459
Reincke M, Bancos I, Mulatero P, et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021; 9 (12): 876–92. https://doi.org/10.1016/S2213-8587(21)00210-2
Hu D, Li J, Zhuang Y, Mao X. Adrenocorticotropic hormone: An expansion of our current understanding of the treatment for nephrotic syndrome. Steroids 2021; 176: https://doi.org/10.1016/j.steroids.2021.108930
Lightman S, Birnie M, Conway-Campbell B. Dynamics of ACTH and cortisol secretion and implications for disease. Endocr Rev 2020; 41 (3): bnaa002. https://doi.org/10.1210/endrev/bnaa002
Reincke M, Bancos I, Mulatero P, et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021; 9 (12): 876–92. https://doi.org/10.1016/S2213-8587(21)00210-2
Hodgson A, Pakbaz S, Mete O. A diagnostic approach to adrenocortical tumors. Surg Pathol Clin 2019; 12 (4): 967–95. https://doi.org/10.1016/j.path.2019.08.005
Fukuoka H, Shichi H, Yamamoto M, Takahashi Y. The mechanisms underlying autonomous adrenocorticotropic hormone secretion in Cushing’s disease. Int J Mol Sci 2020; 21 (23): 9132. https://doi.org/10.3390/ijms21239132
Seccia T, Caroccia B, Maiolino G, et al. Arterial hypertension, aldosterone, and atrial fibrillation. Curr Hypertens Rep 2019; 21 (12): https://doi.org/10.1007/s11906-019-1001-4
Schilbach K, Junnila R, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes 2019; 127 (2-03): 84–92. https://doi.org/10.1055/a-0672-0836
